Background and purpose: Constipation is a common non-motor symptom of Parkinson's disease (PD). Deposition of a-synuclein inclusions that spread from the gut to the substantia nigra through the vagus nerve has recently been speculated to be a pre-motor and early stage of PD. The aim of the study was to investigate whether constipation is associated with dopaminergic pathology on dopamine transporter (DAT) single-photon emission computed tomography in early drug-na€ ıve patients with PD. Our hypothesis was that constipation is associated with other signs of pre-motor PD and is independent of DAT pathology. We then investigated for associations with motor and nonmotor symptoms, and with cerebrospinal fluid biomarkers of PD pathology. Methods: Using the Parkinson's Progression Markers Initiative database, we investigated the prevalence of constipation and the association between constipation and clinical features, striatal [
Introduction
Constipation is a common and bothersome nonmotor symptom of Parkinson's disease (PD), which is often poorly identified and inadequately treated [1, 2] . Similar to other non-motor symptoms [3, 4] , non-dopaminergic pathways could be implicated in the development of constipation in PD [5] . Impairment of the autonomic nervous system in the gut, leading to a reduction of colonic transit time, may be responsible for the development of constipation in PD [6] . Post-mortem studies have shown that deposition of a-synuclein inclusions in the gut occurs early in the course of PD [7] and abnormal a-synuclein agglomeration spreading from the gut to the substantia nigra via the vagus nerve may be the primum movens of PD [8] .
Experimental studies showed that rats microinjected with 6-hydroxydopamine into the bilateral substantia nigra exhibit constipation, and the decrease in daily faecal production and amplitude of colonic spontaneous contraction was correlated with the reduction in dopaminergic neurons in the substantia nigra [9] . In humans, evidence in patients with established and advanced PD suggests that dopaminergic medication exacerbates constipation [10] . However, it is unclear whether constipation in PD is associated with markers of motor pathology, such as the dopaminergic degeneration in the striatum.
Here, in early drug-na€ ıve patients with PD, we aimed to investigate whether constipation was associated with dopaminergic pathology on dopamine transporter (DAT) single-photon emission computed tomography (SPECT). Our hypothesis was that constipation is associated with other signs of pre-motor PD and is independent of DAT pathology. We then investigated for associations with motor and nonmotor symptoms, and with cerebrospinal fluid (CSF) biomarkers of PD pathology, such as a-synuclein levels.
Methods
Details of the clinical assessments, dopaminergic imaging, CSF and serum samples, and statistical analyses have been included in Data S1.
Results
The prevalence of constipation was 33.2% (132/398) in the early de-novo patients with PD, and was higher compared with age-and gender-matched healthy controls (12.7%; 24/189; P < 0.0001). The severity of constipation was similar in PD and controls (1.26 AE 0.52 in PD vs. 1.17 AE 0.482 in controls; P = 0.391). Patients with PD with constipation were older (P < 0.001) and had worse postural instability scores than patients with PD without constipation (P = 0.004). Patients with PD with constipation had higher burdens of non-motor symptoms compared with patients with PD without constipation and, specifically, higher rapid eye movement behavioural disorder (P < 0.0001) and depression (P = 0.008) scores. No other clinical differences were found between patients with PD with and without constipation (Table 1) and serum insulin-like growth factor 1, urate and glucose) biomarkers between patients with PD with and without constipation (all P > 0.10; Table 2 ).
As constipation was associated with older age in patients with PD (r = 0.728, P < 0.001), we used age as a covariate. Worse constipation scores in patients with PD Mann-Whitney U-tests). Data are shown as mean AE SD or % (n). correlated with higher Movement Disorder SocietySponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total (r = 0.285, P < 0.001), MDS-UPDRS Part I (r = 0.454, P < 0.001), MDS-UPDRS Part II (r = 0.217, P < 0.001) and MDS-UPDRS Part III (r = 0.104, P = 0.037) scores. Worse constipation scores were associated with increased postural instability (r = 0.190, P = 0.012), higher REM sleep behavior disorder (RBD) score (r = 0.228, P < 0.0001) and depression scores (r = 0.187, P = 0.024). No correlations were found for other clinical variables, imaging and non-imaging biomarkers.
Discussion
Our findings demonstrate that constipation is not associated with molecular markers of PD pathology, including [
123 I]Ioflupane SPECT or CSF a-synuclein levels. [
123 I]Ioflupane SPECT assesses the integrity of dopamine transporters and is a marker of pre-synaptic dopaminergic terminal degeneration and a correlate of rigidity and bradykinesia in PD [11] . Also, constipation in patients with early untreated PD was not associated with the severity of cardinal motor symptoms of PD, such as rigidity, bradykinesia and tremor. These results provide evidence for a non-dopaminergic substrate underlying the development of constipation in PD. Our data show that the severity of constipation is associated with RBD and depression, which are speculated to be pre-motor symptoms of PD. We also found a threefold increased prevalence of constipation in patients with early untreated PD compared with the age-and gender-matched healthy population, and confirm that constipation is a common and early feature of PD.
Three mechanisms could potentially be responsible for constipation: slow transit time, rectal evacuation disorder and mixed constipation [12] . Slow transit time has been demonstrated to be the main mechanism involved in constipation of patients with PD and is characterized by a prolonged colonic transit time and reduced number of high-amplitude colonic propulsions and contractions [13] . A lower number of bowel movements has been also directly correlated with an increased risk of PD in the Honolulu Heart Program study [14] . A dysfunction of the enteric nervous system was proven to cause slow transit time and then the symptom of constipation in PD [15] . This dysfunction might be initiated by several triggers, including neuroinflammation [16] , abnormalities of gut microbiota [17] and small intestinal bacterial overgrowth [18] that led to abnormal a-synuclein deposition. This impairs the autonomic nervous system and might also explain the development of other nonmotor symptoms that we found to be associated with constipation.
In previous studies on patients with PD, constipation was already associated with the presence of RBD [19] [20] [21] and depression [22] . These non-motor symptoms have been demonstrated to occur many years before the onset of motor symptoms of PD, and are referred to as a condition called 'pre-motor PD' [23] . During this prodromal stage, neurodegenerative processes have begun and subjects are at high risk of developing PD, although motor symptoms permitting the diagnosis are not well demarcated. It was demonstrated that subjects with constipation, RBD and depression had a 2.36-, 3.69-and 2.82-fold risk, respectively, of developing PD with an average interval between pre-motor and motor onset of 4-6 years [24] . An impairment of pre-synaptic sympathetic and parasympathetic terminals due to an abnormal asynuclein deposition might be quantified by [
123 I]-metaiodobenzylguanidine SPECT and might underlie constipation [25] , RBD [26] and depression [27] in PD. This leads to the formation of Lewy bodies and to trans-synaptic cell-to-cell transmission of PD pathology from the autonomic nervous system of the gut to the substantia nigra and further areas of the central nervous system via the vagus nerve [6, 28, 29] .
However, we did not find any associations between anosmia and constipation, as indicated previously [30] . This might be explained by the fact that anosmia also correlated with the duration of the disease [31] and our patients had an average disease duration of only 6 months. The progression of the disease also has an effect on constipation, with patients with advanced disease showing higher prevalence of constipation [10, 32] . This might be related to both the increased levodopa equivalent dosage due to the progression of the disease [10] and the progression of the disease itself, with further degeneration of non-dopaminergic pathways [32] . As a possible pathogenesis of PD, Braak's theory suggests that progressive accumulation of Lewy bodies from the periphery (dorsal motor nucleus of the vagus and olfactory bulb) to the central nervous system correlated with clinical presentation at the different stages of the disease [33] , although several studies have challenged this view [34, 35] . In these studies, about 10% of patients with PD had no a-synuclein in the dorsal motor nucleus of the vagus [34, 35] , despite the fact that a-synuclein was present in the substantia nigra and cortical regions [34] . These findings do not support Braak's hypothesis of ascending and spreading pathology in PD. An alternative theory [29] suggests that multiple pathways might simultaneously accumulate misfolded proteins in PD and each system may reach its individual threshold for symptoms at different rates (e.g. lower thresholds for periphery and brainstem regions, and higher for midbrain). Consequently, constipation, RBD and depression, which appear earlier than the motor symptoms, might be due to damage to the peripheral nervous system and brainstem, which have a lower pathological threshold for symptoms compared with the midbrain. This functional threshold theory explains our findings better than the ascending spread theory for PD.
In line with this evidence, we did not find any difference in PD pathology (CSF a-synuclein) or dopaminergic denervation (DaTSCAN TM ) in constipated versus non-constipated patients with PD, despite a worse clinical phenotype. This represents the main novel finding of this study and confirms the hypothesis that the mechanisms underlying constipation, and the other pre-motor symptoms associated with it, are mainly non-dopaminergic. However, CSF pathology is only an indirect surrogate of pathological processes in the brain, and the reason for constipated and non-constipated patients with PD having similar levels of a-synuclein in our study can be related to the limits of this technique.
It is important to emphasize that only one-third of our population had constipation. The presence of this symptom may be suggestive of a specific premotor subphenotype of PD that is characterized by constipation, RBD, depression and autonomic dysfunction. This PD subtype was previously suggested by Van Rooden et al. [36] . They demonstrated that the presence of constipation, sleep problems, depression, autonomic dysfunctions and worse axial symptoms describes a PD subtype that might also be reflected in our population. In agreement with the threshold theory [29] , another hypothesis is that some patients with PD have developed motor symptoms and not constipation because the pathology might have reached the threshold for symptoms in the midbrain but not in the autonomic system. This concept might also be valid for the other pre-motor symptoms that correlate with constipation, such as RBD and depression. Previous studies have shown no differences in dopaminergic denervation (DaTSCAN   TM   ) in patients with PD with and without RBD, as we found here for constipation [37, 38] . However, anxiety and depression have previously been associated with greater dopaminergic denervation (DaTSCAN TM ) in PD [39] . This reinforces the concept that constipation and RBD might largely share a common pathway, with a similar pathological threshold for symptoms, but this is partially true for depression and anxiety, which might also be due to the damage to the dopaminergic system.
The association between constipation and postural instability also suggests that damage to the non-dopaminergic system might underlie this phenotype [40] . However, although a statistically significant difference was observed in the postural instability subscore, it may be clinically negligible (mean 1.0 vs. 0.7), raising the possibility that this was related to the early stages of PD during clinical assessments. Constipated patients with PD might have had both dopaminergic and cholinergic dysfunction since the early stage of the disease. The remaining 70% of patients with PD without constipation might have developed PD starting from a different subset of pre-motor symptoms, without having reached a threshold of damage in the autonomic system [29] . The identification of PD subtype, exploring the heterogeneous pre-and non-motor PD phenotype, might help in the discovery of the aetiologies of the disease and lead in the future to neuroprotective treatments specific for each patient with PD.
To the best of our knowledge, this is the first study to have identified no contribution of dopaminergic degeneration to constipation in a cohort of early-stage, denovo patients with PD. Constipation, evaluated using a single item (constipation, 1.11) from a validated scale (MDS-UPDRS Part I), offers a uniform measure applicable across an array of PD stages, congruous with the NIH Common Elements program goals. However, this also represents a limitation of our study. MDS-UPDRS Part I item 1.11 is a highly subjective scale and the perceived prevalence of constipation is not accurate if compared with specific constipation scales, such as the Roma III scale, Constipation Assessment Scale, etc. In addition, there is no measure of weekly bowel movements or change in number of bowel movements compared with the previous pattern. Furthermore, the item is not able to help in differentiating the distinct types of constipation described in PD. In addition, the assumption that patient symptoms ascertained by questionnaires (subjective) are equivalent to function (objective) is, obviously, not true. Thus, the rapid eye movement sleep behavior disorder questionnaire does not measure RBD severity but the subjective burden of RBD symptoms presumed to be related to RBD severity. Subjective questionnaires may also underestimate the prevalence of RBD and be an inaccurate guide to its severity. Another shortcoming of the Parkinson's Progression Markers Initiative (PPMI) study is the absence of long-term follow-up. Our patients had an average disease duration of 6 months and the presence of patients with multiple system atrophy misdiagnosed as PD cannot be excluded. Finally, data on cardiac [123I] meta-iodobenzylguanidine scintigraphy could be useful to better support our hypothesis, but patients with PD did not undergo this assessment during the PPMI study.
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